1/ Our new review is out today in Nature Reviews Cancer—on why therapeutic cancer vaccines are finally gaining traction after decades of setbacks. 🔗 rdcu.be/emkkd w/ @NeehaZaidi @DrLizJaffee Key takeaways below

New study led by @danielzabransky.bsky.social lab Older adults respond well to anti-PD1 therapy, despite age-related immune changes 🔗 nature.com/articles/s41... Findings unlikely to extend to other forms of immunotherapy (eg cancer vaccines, etc.) which rely on naive T cells

Nakazawa et al. studied the peripheral immune profile of a cohort of patients with advanced solid tumors; 54 patients received anti-PD-(L)1 alone and 50 received anti-PD-(L)1 + anti-CTLA-4. bit.ly/42qWx4d   @markyarchoan.bsky.social

Anti-vascular endothelial growth factor enhances immune checkpoint inhibition by reprogramming regulatory T cells into a fragile state @cp-immunity.bsky.social @markyarchoan.bsky.social www.cell.com/immunity/ful... on www.cell.com/immunity/ful...

1/ Exciting work published in Immunity from @TimGreten et al. showing that anti-VEGF enhances the antitumor activity of PD-L1 + CTLA-4 blockade by inducing a fragile Treg phenotype via BAFF and IL-12 📄 www.cell.com/immunity/ful...

🚨 New manuscript led by Marina Baretti Using #CODEX multiplexed imaging: 🧬 #CCA is rich in CAFs,TAMs,MDSCs, scarce CD8 T cells (~1.8% of all cells) 🧬 FGFR2 fusions → ⬆️ CD11b+/CD15+ granulocytes 🧬 IDH1 mutations → trend ⬆️M2-like mac ▶️ pubmed.ncbi.nlm.nih.gov/39969434/

Our first 2025 paper was published today in JITC Explores the "obesity paradox" in cancer immunotherapy: 1️⃣ Obese patients have better IO outcomes (despite ⬆️cancer risk) 2️⃣ Obesity → ⬆️T-cell exhaustion →⬆️ ICI benefit doi.org/10.1136/jitc...

Excited to share our latest study in Nature Immunology on TLS in #HCC patients treated w/ neoadj ICB: ⏩ TLS linked to improved outcomes ⏩ Novel "involuted" TLS found in tumor regression zones 🔗 nature.com/articles/s41...